Evaluation of the resazurin microtiter assay for rapid detection of of loxacin resistance in M-tuberculosis

被引：0
作者：
Umubyeyi, A. N. [1 ]
Martin, A.
Zissis, G.
Struelens, M.
Karita, E.
Portaels, F.
机构：
[1] Inst Trop Med Prince Leopold, Mycobacteriol Unit, B-2000 Antwerp, Belgium
[2] CHU St Pierre, Dept Microbiol, St Pierre, Belgium
[3] Free Univ Brussels, Erasme Hosp, Dept Microbiol, B-1050 Brussels, Belgium
[4] Emory Univ, Project San Francisco, Kigali, Rwanda
来源：
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2006年 / 10卷 / 07期
关键词：
M; tuberculosis; MIC evaluation; resazurin; second-line drug; quinolone;
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
OBJECTIVE: To evaluate the performance of the colorimetric resazurin microtiter assay (REMA) method for the detection of ofloxacin resistance. METHODS: A panel of 120 multidrug-resistant Mycobacterium tuberculosis strains was tested blindly by the REMA method and compared with the results obtained using the BACTEC 460 method. RESULT: A very good correlation was observed between the two methods. CONCLUSION: The REMA method is simple, rapid and can be an inexpensive alternative procedure for the rapid detection of anti-tuberculosis drug resistance in laboratories with limited resources.
引用
收藏
页码：808 / 811
页数：4
相关论文
共 28 条
  • [1] [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
  • [2] Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada
    Bozeman, L
    Burman, W
    Metchock, B
    Welch, L
    Weiner, M
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (03) : 386 - 391
  • [3] Bryskier A, 2002, EXPERT OPIN INV DRUG, V11, P233
  • [4] Standard short-course chemotherapy for drug-resistant tuberculosis -: Treatment outcomes in 6 countries
    Espinal, MA
    Kim, SJ
    Suarez, PG
    Kam, KM
    Khomenko, AG
    Migliori, GB
    Baéz, J
    Kochi, A
    Dye, C
    Raviglione, MC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (19): : 2537 - 2545
  • [5] Global trends in resistance to antituberculosis drugs
    Espinal, MA
    Laszlo, A
    Simonsen, L
    Boulahbal, F
    Kim, SJ
    Reniero, A
    Hoffner, S
    Rieder, HL
    Binkin, N
    Dye, C
    Williams, R
    Raviglione, MC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (17) : 1294 - 1303
  • [6] Espinal MA, 1999, INT J TUBERC LUNG D, V3, P561
  • [7] The global situation of MDR-TB
    Espinal, MA
    [J]. TUBERCULOSIS, 2003, 83 (1-3) : 44 - 51
  • [8] Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus"
    Farmer, P
    Kim, JY
    [J]. BRITISH MEDICAL JOURNAL, 1998, 317 (7159) : 671 - 674
  • [9] Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis
    Fattorini, L
    Iona, E
    Ricci, ML
    Thoresen, OF
    Orrù, G
    Oggioni, MR
    Tortoli, E
    Piersimoni, C
    Chiaradonna, P
    Tronci, M
    Pozzi, G
    Orefici, G
    [J]. MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1999, 5 (04): : 265 - 270
  • [10] Fluoroquinolones, tuberculosis, and resistance
    Ginsburg, AS
    Grosset, JH
    Bishai, WR
    [J]. LANCET INFECTIOUS DISEASES, 2003, 3 (07) : 432 - 442
123